Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Two Dose Levels of FT2109 in Biologic Naïve and Biologic Experienced Participants With Active Psoriatic Arthritis (PsA)

NCT07869134 is registered in ClinicalTrials.gov with Forward Therapeutics as lead sponsor.

NCT NCT07869134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Two Dose Levels of FT2109 in Biologic Naïve and Biologic Experienced Participants With Active Psoriatic Arthritis (PsA)
Lead sponsor
Forward Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
November 30, 2027
Enrollment
210 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis (psa)